Table 1.

Study subjects

CharacteristicsTotal (n = 37)
Age (median; range)59 (39–88)
HR status
 Any HR+33 (89%)
 ER+, PR7 (19%)
 PR+, ER4 (11%)
 Both ER+ and PR+ (HR+)22 (60%)
Receptor group
 HR+/Her231 (84%)
 HR+/Her2+2 (5%)
 HR/Her24 (11%)
Prior hormonal therapy
 % Adjuvant22 (59%)
 % Advanced31 (84%)
 # Advanced lines (median, range)2 (0–5)
 0 or 1 line of therapy13 (35%)
 ≥2 lines of therapy24 (65%)
Prior chemotherapy
 % Adjuvant26 (70%)
 % Advanced34 (92%)
 # Advanced lines (median, range)2 (0–13)
 0 or 1 line of therapy9 (24%)
 ≥2 lines of therapy28 (76%)